Following her related presentation at CHEST 2020, Terri Weaver (University of Illinois Chicago, Chicago, IL, USA) took the time to speak with us about the long term effects of solriamfetol on excessive daytime sleepiness and functional outcomes in participants with obstructive sleep apnea.
Questions
1. What is known about the long and short term efficacy of solriamfetol in the treatment of obstructive sleep apnea? (0:05)
2. Could you give us an overview of the aims and design of the study you are presenting? (1:00)
3.What were the major findings of this study? (1:47)
4.Were there any side effects reported in the study? (3:55)
5.What are the implications of these findings for clinical practice? (4:41)
6.Which patients are most likely to benefit from solriamfetol and in whom is it contraindicated? (6:15)
Disclosures: Terri Weaver has received royalties for the use of the FOSQ from Philips Respironics and has acted as a speaker/consultant/advisor for ResMed, ResMed Germany, Merck Co, Inc., Nyxoah, Jazz Pharmaceuticals, Cook Medical, RWS, Verily Life Sciences, Stratevi, WCG MedAvante Prophase, Evidation Health, Inc. and Bayer AG.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the CHEST 2020 Annual Meeting (Virtual).
